Eye infection LoaLoa
Conditions
Interventions
no intervention
Albendazole 21 days
Albendazole -Albendazole
Albendazole and ivermectine
Sponsors
Ayola Akim Adegnika
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: -Adult, male participants in the BuDiLoLo study -L. loa microfilaria < 50,000 mf/mL -Intention to remain residing in study area and comply with study procedures throughout 6 month follow-up period -Signed written informed consent
Exclusion criteria
Exclusion criteria: -Patients treated with albendazole during the 4 previous weeks -Known intolerance or allergy to any study drug -Viral hepatitis (HBV, HCV) or other known active liver disease -HIV or other known immunosuppressive condition -History of epilepsy, encephalitis, meningitis or encephalopathy -Any other acute or chronic medical condition, medication or psychosocial factor(s) deemed by the Investigator to put the potential participant at greater than acceptable risk or to significantly affect study outcomes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary efficacy endpoint will be the proportion of subjects with L. loa microfilarial levels <100 mf/mL ;the proportion of subjects without microscopically detectable microfilariae | — |
Secondary
| Measure | Time frame |
|---|---|
| the occurrence of any grade 3 adverse event (AE) or serious adverse event (SAE) ;be assessed by the occurrence of all (grade 1-2) adverse events at least possibly related to study therapy;3. Proportion of subjects without peripheral microfilaraemia | — |
Countries
Gabon
Contacts
Public ContactMichael Ramharter
professor
Outcome results
None listed